Systematic review of targeted extracellular vesicles for drug delivery – Considerations on methodological and biological heterogeneity: Considerations on methodological and biological heterogeneity

Johann Mar Gudbergsson*, Katrine Jønsson, Jens Bæk Simonsen, Kasper Bendix Johnsen

*Corresponding author for this work

Research output: Contribution to journalReviewResearchpeer-review

Abstract

The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.
Original languageEnglish
JournalJournal of Controlled Release
Volume306
Pages (from-to)108-120
ISSN0168-3659
DOIs
Publication statusPublished - 2019

Keywords

  • Extracellular vesicles
  • Exosomes
  • Microvesicles
  • Drug delivery
  • Liposomes
  • Nanoparticles
  • Pharmacokinetics
  • Kinetics
  • Treatment

Cite this

@article{6b5dce269ee04c6da44f01f37d02191e,
title = "Systematic review of targeted extracellular vesicles for drug delivery – Considerations on methodological and biological heterogeneity: Considerations on methodological and biological heterogeneity",
abstract = "The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.",
keywords = "Extracellular vesicles, Exosomes, Microvesicles, Drug delivery, Liposomes, Nanoparticles, Pharmacokinetics, Kinetics, Treatment",
author = "Gudbergsson, {Johann Mar} and Katrine J{\o}nsson and Simonsen, {Jens B{\ae}k} and Johnsen, {Kasper Bendix}",
year = "2019",
doi = "10.1016/j.jconrel.2019.06.006",
language = "English",
volume = "306",
pages = "108--120",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Systematic review of targeted extracellular vesicles for drug delivery – Considerations on methodological and biological heterogeneity

T2 - Considerations on methodological and biological heterogeneity

AU - Gudbergsson, Johann Mar

AU - Jønsson, Katrine

AU - Simonsen, Jens Bæk

AU - Johnsen, Kasper Bendix

PY - 2019

Y1 - 2019

N2 - The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.

AB - The idea of using extracellular vesicles (EVs) for targeted drug delivery was first introduced in 2011 and has since then gained increasing attention as promising new candidates in the field. Targeting EVs to areas of disease can be achieved through a complex process of designing and inserting a targeting ligand to the surface of the EVs. Although this can be obtained via chemical conjugation, the most important strategy has been to transfect or modulate the EV-producing cell to endow the EVs with the desired targeting capabilities. However, since EVs are harvested from biological sources, their composition is highly heterogeneous, which makes it difficult to control the purity and quality of the resulting EV-based drug delivery vehicles. In this review, we present a detailed account of EVs in targeted drug delivery based on a systematic literature search. We discuss the potential advantages of EVs compared to synthetic lipid-based nanocarriers, and the methodological and biological limitations associated with their use as targeted drug delivery vehicles.

KW - Extracellular vesicles

KW - Exosomes

KW - Microvesicles

KW - Drug delivery

KW - Liposomes

KW - Nanoparticles

KW - Pharmacokinetics

KW - Kinetics

KW - Treatment

U2 - 10.1016/j.jconrel.2019.06.006

DO - 10.1016/j.jconrel.2019.06.006

M3 - Review

C2 - 31175896

VL - 306

SP - 108

EP - 120

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -